公开(公告)号：US20160000735A1

公开(公告)日：2016-01-07

申请号：US14769504

申请日：2014-02-26

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Pothana SAIKUMAR ,  Prajjal Kanti SINGHA

IPC: A61K31/19 ,  G01N33/574 ,  A61K45/06 ,  C12N15/113

CPC classification number: A61K31/19 ,  A61K45/06 ,  A61K2039/505 ,  C12N15/1138 ,  C12N2310/531 ,  C12N2320/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57484 ,  G01N2333/4704 ,  G01N2800/52

Abstract: The invention provides methods for classifying a cancer as susceptible to transmembrane prostate androgen induced (TMEPAI)-directed therapies, and methods for treating such cancers. The field of the invention pertains generally to medicine, pathology and oncology. More particularly, it addresses the treatment of breast cancer, such as triple-negative breast cancer, using a transmembrane prostate androgen induced (TMEPAI)-directed therapy.

Abstract translation: 本发明提供了将癌症分类为易于跨膜前列腺雄激素诱导（TMEPAI） - 定向治疗的方法，以及用于治疗这种癌症的方法。 本发明的领域通常涉及药物，病理学和肿瘤学。 更具体地，它涉及使用跨膜前列腺雄激素诱导（TMEPAI）靶向治疗来治疗乳腺癌，例如三阴性乳腺癌。